# An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

> **NCT00454584** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 903 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CNTO 1275 45 mg
- **DRUG:** CNTO 1275 90 mg
- **DRUG:** Etanercept 50 mg

## Key facts

- **NCT ID:** NCT00454584
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-01
- **Final completion:** 2009-01
- **Target enrollment:** 903 (ACTUAL)
- **Last updated:** 2012-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454584, "An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00454584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*